9 / 100

SEATTLE – (OCT. 11, 2022) – People living with HIV must be included in clinical trials for new tuberculosis vaccine candidates currently in the development pipeline, say experts on an international panel convened last year to address gaps in the current TB vaccine landscape.

Their recommendations, which appear in a new paper published Oct. 11, 2022, in The Lancet HIV, are designed to shape the future of TB vaccine development and help ensure people living with HIV have access to safe and effective TB vaccines like those for the general population.

The panel was convened by the DAIDS Cross-Network TB Vaccine Working Group comprised of the HIV Vaccine Trials Network (HVTN), the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT). The three networks worked collaboratively with the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) and its Division of AIDS.

Meeting at a series of symposia in January and February 2021, panel members developed consensus statements that serve as strategic recommendations designed to address current TB vaccine gaps and prioritize clinical trials for people with HIV.

“People living with HIV are at high risk for tuberculosis infection and subsequent disease and tend to develop less robust vaccine-induced immune responses,” said James G. Kublin, MD, executive director of HVTN, which is based at Fred Hutchinson Cancer Center, and co-senior author of the paper. “Yet, many questions remain unanswered about developing an effective TB vaccine for this group.”

Background

Tuberculosis was responsible for 1.5 million deaths in 2020 and continues to pose a threat to global health, particularly for those living in nations with high TB incidence. The World Health Organization estimated that almost 10 million people developed the disease in 2020, 8% of whom were coinfected with HIV. That translated to almost 800,000 diagnosed cases that caused some 214,000 deaths among people living with HIV.

The paper notes that people living with HIV have a 15- to 21-fold greater likelihood of developing TB disease and dying from it compared with those not living with HIV. That’s likely due to HIV-associated immunosuppression that results in a weaker immune response and lower vaccine efficacy for people living with HIV.

“TB remains the leading cause of morbidity and mortality in people with HIV, and those with advanced HIV disease have the highest risk for TB disease,” said Gavin Churchyard, MBBCH, FCP (SA), FRCP (Edin), MMED, PhD, founder and CEO of The Aurum Institute NPC, a member of HVTN and ACTG, and co-senior author on the article. “Even with antiretroviral therapy (ART) lowering viral loads to undetectable levels, people living with HIV remain at significantly greater risk for TB and worse outcomes than the general population.”

Moreover, people living with HIV historically have been excluded from TB vaccine trials so developers could maximize the ability to demonstrate strong immunity and effectiveness with their vaccine candidates, Kublin explained. There also have been concerns about using live-attenuated vaccines, such as Bacillus Calmette-Guérin (BCG), in people living with HIV who are not on ART, for fear of spreading live bacteria.

It is important to note that even among persons living with HIV, some communities are often excluded from TB vaccine trials – children, adolescents and pregnant women.

“It is critical that persons living with HIV across the lifespan be included in TB vaccine trials,” said Amita Gupta, MD, MHS, FIDSA, director of the Division of Infectious Diseases at Johns Hopkins School of Medicine, vice-chair of the IMPAACT TB Scientific Committee and a study co-author. “Data for children, adolescents and pregnant women are much-needed but are often slow to be generated. The goals of TB elimination require novel TB vaccines, and we must focus on these populations who are at especially high risk for TB disease after exposure,” Gupta added.

Gap in New Road Map

Recently, the Amsterdam Institute for Global Health & Development, in cooperation with the European & Developing Countries Clinical Trials Partnership, produced a comprehensive road map with short- and long-term goals for TB vaccine research and development.

But the road map had a glaring omission: It failed to specifically address TB vaccines in people living with HIV.

“That oversight served as the impetus for gathering the expert panel tasked with making strategic recommendations to address these gaps for people living with HIV and establish priorities for future TB vaccines,” said Kublin.

“Our paper with the panel’s recommendations makes a strong case for including people living with HIV in clinical development of TB vaccines as early as possible,” Churchyard concluded. “Doing so will help maximize the safety and effectiveness of TB vaccines for this at-risk group while benefiting the population at large.”

# # #

DOI: 10.1016/S2352-3018

Post Embargo Link: https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00255-7/fulltext

About the HIV Vaccine Trials Network (HVTN)

HVTN is an international collaborative based at the Fred Hutchinson Cancer Center in Seattle to facilitate the evaluation of vaccines to prevent HIV/AIDS, as well as tuberculosis and COVID-19. It is the world’s largest publicly-funded international collaboration facilitating the evaluation of vaccines to prevent HIV/AIDS. The HVTN helps advance the field of vaccinology, social and behavioral sciences, statistics and immunology, as well as tuberculosis and COVID-19 vaccines. The HVTN’s mission is to fully characterize the safety, immunogenicity and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV globally. Funding is provided by public and private sources. The National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health, is the primary funder and sponsor of the majority of trials conducted by the HVTN. The Network’s headquarters are at the Fred Hutchinson Cancer Center in Seattle, Washington.

About the ACTG

Founded in 1987, the AIDS Clinical Trials Group (ACTG) was the world’s first HIV research network. The ACTG conducts groundbreaking studies to improve the treatment of HIV and its complications, including tuberculosis and viral hepatitis; reduce new infections and HIV-related illness; and advance new approaches to prevent, treat, and ultimately cure HIV in adults and children. More recently, the ACTG has expanded its focus to include the evaluation of outpatient treatments for COVID-19 and monkeypox. ACTG investigators and research units in 15 countries serve as major resources for HIV/AIDS, tuberculosis, and viral hepatitis research, treatment, care, and training/education in their communities. ACTG studies have helped establish current paradigms for managing these infectious diseases and have informed multiple treatment guidelines.

About the IMPAACT Network

The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is a global collaboration of investigators, institutions, community representatives, and other partners organized for the purpose of evaluating prevention and treatment interventions for HIV and HIV-associated complications and co-morbidities in infants, children, and adolescents, and during pregnancy and postpartum through the conduct of high-quality clinical trials. The Network evaluates novel and durable treatments for both HIV and TB, strategies for antiretroviral treatment-free HIV remission/cure, and strategies to address the complications and co-morbidities affecting these populations of interest with or at risk of HIV. IMPAACT trials have led to changes in global HIV and TB treatment guidelines and to licensure of new antiretrovirals (ARVs) and new formulations of ARVs as well as to development of other interventions for these key populations. The Network is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH).

MEDIA CONTACTS:

HVTN
Sandy Van
svan2@fredhutch.org
808.206.4576

ACTG
Jenna Conley
jenna@conleycommunications.net
215.684.9476

IMPAACT NETWORK
Kyle Hayden
khayden@fhi360.org
919-544-7040


Source link

The NIH/DAIDS Cross-Network (ACTG/HVTN/IMPAAC | EurekAlert!

You May Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *